New pill hopes to tackle tough lymphoma

NCT ID NCT04993690

Recruiting now Disease control Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial is testing an experimental drug called LP-168, taken as a pill, in adults with B-cell lymphoma that has come back or not responded to standard treatments. The study aims to find the safest dose and check for side effects in about 200 participants. It is too early to know if the drug works, but researchers will also look for signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LP-168 tablet
What this could lead to: If it works, this could point toward a new oral treatment option for people with B-cell lymphoma who have not responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial, so the drug may not be effective or safe. It is small and focused on finding the right dose, not proving a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia B-cell neoplasm diffuse large B-cell lymphoma follicular lymphoma mantle cell lymphoma marginal zone lymphoma Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B CELL LYMPHOMA

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China
Peking University Third Hospital
RECRUITING

Beijing, Beijing Municipality, 100089, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.